Abstract
Background:
Hepatocellular carcinoma (HCC) accounts for the majority of primary liver cancers. Worldwide, liver cancer is the fourth most common cause of cancer-related death. Recent studies have found that PIWI-interacting RNAs (piRNAs) participate in the occurrence and development of various tumors and are closely related to the growth, invasion, metastasis and prognosis of malignant tumors. Studies on the role and functional mechanism of piRNAs in HCC development and progression are limited.
Methods:
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) were used to detect the expression of piR-017724 in both HCC tissues and cells. Based on the clinical data of HCC patients, the clinical and prognostic value of piR-017724 was further analyzed. Then, targeted silencing and overexpressing of piR-017724 in HCC cells was further used to examine the biological functions of piR-017724. In addition, the downstream target protein of piR-017724 was predicted and validated through high-throughput sequencing and public databases.
Results:
The piR-017724 was significantly downregulated in HCC tissues and cells, and the downregulation of piR-017724 was associated with tumor stage and poor prognosis in HCC. The piR-017724 inhibitor promoted the proliferation, migration and invasion of HCC cells, while the piR-017724 mimic had the opposite effect. However, the piR-017724 did not affect apoptosis of HCC cells. High-throughput sequencing and qRT-PCR confirmed a reciprocal relationship between piR-017724 and PLIN3. Therefore, we speculate that piR-017724 may inhibit the development and progression of HCC by affecting the downstream protein PLIN3.
Conclusions:
Our study shows that piR-017724, which is lowly expressed in HCC, inhibits the proliferation, migration and invasion of HCC cells and may affect the development of hepatocellular liver cancer through PLIN3, which provides new insights into the clinical application of piR-017724 in the treatment of hepatocellular carcinoma.
Introduction
Liver cancer is one of the most common malignancies worldwide and is also a leading cause of cancer-related death (1). The proportion of hepatocellular carcinoma (HCC) among primary liver cancer cases worldwide is 75%-85%, while this rate has increased sharply to 93.0% in China (2, 3). Risk factors for hepatocellular carcinoma include autoimmune hepatitis, alcoholism, diabetes, and chronic hepatitis B virus (HBV) infection (4–6). Although there are many immunotherapies and targeted therapies for HCC, HCC patients generally still have poor prognosis with a high probability of postoperative recurrence and metastasis (7–9). Because of the high rate of recurrence and metastasis, HCC patients are often diagnosed with a poor prognosis, especially in the terminal stages (10). HCC involves multiple changes in gene expression; therefore, understanding these changes is important for identifying new and significant genes in the pathogenesis of the disease. This diversity could help promote promising therapies for HCC. Therefore, to develop new therapeutic strategies to reduce the mortality of this malignancy, it is necessary to further elucidate the molecular pathogenesis of HCC.
PIWI-interacting RNAs (piRNAs) have become a new research hotspot in recent years. piRNA is a noncoding RNA whose length is approximately 26 to 31 nucleotides. It interacts with PIWI protein family members specifically expressed in germ cells to form the piRNA silencing complex (piRISC). piRNA/PIWI complexes affect transposon silencing, spermatogenesis, genome rearrangement, epigenetic regulation, protein regulation, and germline stem cell maintenance (11). Although little is known about the function of piRNAs in human cancer, emerging studies suggest that piRNAs may play an important role in cancer development and progression and may serve as diagnostic and prognostic biomarkers (12–15).
In the current work, we have studied the expression level of hsa_piR_017724 in HCC and its correlation with prognosis for the first time, and we have proposed the downstream PLIN3 network of hsa_piR_017724 to further explore its potential role in the pathogenesis of HCC.
Materials and methods
Patients and samples
Neoplastic liver tissues and matched adjacent nonneoplastic liver tissues were collected from 45 patients undergoing radical hepatocellular carcinoma surgery at the Nantong Third People’s Hospital. Informed consent was obtained from recruited patients, and the study protocol was approved by the Clinical Research Ethics Committees of Nantong Third People’s Hospital. All cases were reviewed by experienced pathologists who confirmed the diagnosis of HCC. Patient statistics are listed in Table 1.
Table 1
| Clinical characteristic | No. (%) or median (IQR) |
|---|---|
| Sex | |
| Male | 35 (79.55%) |
| Female | 9 (20.45%) |
| Age | |
| ≥60 | 20 (45.45%) |
| <60 | 24 (54.55%) |
| Tumor size, cm | 4.28 ± 2.20 |
| Tumor stage | |
| I-II | 12 (27.27%) |
| III-IV | 32 (72.73%) |
| Vascular invasion | |
| Yes | 13 (29.55%) |
| No | 7 (15.91%) |
| Missing | 24 (54.54%) |
| AFP, ng/mL | 147.50 [3.68, 1348.72] |
| ALT, U/L | 28.50 [19.00, 46.25] |
| AST, U/L | 31.00 [26.75, 46.50] |
Clinical characteristics of the included patients.
Cell culture
Human HCC cell lines (SMMC-7721, Li-7, PLC/PRF/5, SK-HEP-1, Huh-7, MHCC-97H, HCC-LM3) and the normal human hepatic cell line (L‐02) were purchased from Shanghai Cell Bank. The normal human hepatic cell line (L‐02) and human HCC cell lines (SMMC-7721, Li-7) were cultured in RPMI‐1640 (Gibco, Thermo Fisher Scientific, Waltham, MA). Human HCC cell lines (PLC/PRF/5, SK-HEP-1) were cultured in MEM (supplemented with NaHCO3 and sodium pyruvate). Human HCC cell lines (Huh-7, MHCC-97H, HCC-LM3) were cultured in Dulbecco’s modified Eagle’s medium (Gibco, Thermo Fisher Scientific). All the media contained 10% fetal bovine serum (FBS; Cell Sciences, Canton, MA). All cells were cultured at 37°C in a humidified incubator under 5% CO2 conditions.
Quantitative reverse transcription-polymerase chain reaction
Total RNA from cell lines and clinical tissues was extracted with TRIzol reagent. To quantify piRNAs, real-time qPCR was performed using the Bulge-LoopTM qPCR kit (RiboBio, Guangzhou, China) according to the manufacturer’s protocol. U6 small nuclear RNA was used as an internal control in both cell lines. All experiments were performed in three biological replicates. The relative expression of RNA was calculated as the power value (2-△△Ct).
Cell transfection
The hsa_piR_017724 mimic, the hsa_piR_017724 inhibitor and the corresponding negative control were synthesized by RiboBio (Guangzhou, China). SMMC-7721 and PLC/PRF/5 cells were seeded in 6-well plates and cultured overnight for transfection. After mixing the two solutions, the mixture was added to a 6-well plate according to the manufacturer’s instructions. Cells were harvested 48 hours after transfection, and the efficiency was verified by PCR.
Cell viability assays
Cell viability was monitored using a Cell Counting Kit-8 (CCK-8, Dojindo, Japan). In brief, 48 h after transfection, HCC cells were seeded into 96-well plates at a density of 3×10^3 cells per well in 100 μl medium and cultured overnight. Cell viability was measured at 2.5 hours after the addition of CCK-8 reagent every 24 hours at OD450.
Colony formation assays
Transfected HCC cells were trypsinized and resuspended to obtain a single cell suspension. Cells were counted and seeded into 6-well plates at a density of 2000 cells per well. The medium was changed every three days, and the cells were cultured for 2 weeks to obtain colonies. Colonies were washed with phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde fixative, and stained with crystal violet (Beyotime). After washing and air drying, cell clones were photographed and counted.
Cell apoptosis analysis by flow cytometry
For the cell apoptosis assay, an Annexin V/7-AAD Apoptosis Detection Kit (BD) was used to stain cells. Both experiments were assessed by flow cytometry using FlowJo software (BD).
Transwell assay
Cell invasion and migration abilities were analyzed by 24-well transwell chambers (Corning, NY, USA) with 8.0 μm pores. At 48 hours after transfection, SMMC-7721 cells and PLC/PRF/5 cells were harvested by trypsin and then suspended in serum‐free medium. The cells were seeded onto the upper chamber at a density of 2×10^5, and the appropriate complete medium with 20% FBS was added to the bottom chamber. After culturing for 24 h in a 37°C, 5% CO2 incubator, cells that stayed in the upper chamber were removed. Cells that migrated through the filter were fixed with 4% paraformaldehyde, washed with PBS, and stained with crystal violet for 8 minutes. For invasion experiments, transwell membranes were precoated with Matrigel (BD Biosciences, San Jose, CA, USA). The number of cells that migrated or invaded was counted in three random fields by using an optical microscope (Olympus, Japan).
Identification of downstream target proteins for piR-017724
The potential target proteins of piR-017724 were predicted by high-throughput sequencing technology combined with bioinformatics analysis, and the prediction results were verified by qRT-PCR.
Statistical analysis
All experiments were performed at least three times. Statistical analysis of all experimental data was performed using SPSS software (version 25.0). GraphPad Prism (version 8.0) was used to determine statistical results. P<0.05 was considered statistically significant.
Results
The piR-017724 is significantly downregulated in HCC tissues and cell lines
First, we verified the expression of piR-017724 in HCC tissues and cell lines by RT−PCR. Compared with normal hepatocytes, we found that piR-017724 levels were significantly downregulated in HCC cells (Figure 1A). Similarly, we found that piR-017724 was expressed at low levels in 45 pairs of liver cancer tissues (Figure 1B).
Figure 1
The piR-017724 downregulation is associated with high malignancy and poor prognosis in HCC patients
Based on the expression data of piR-017724, we divided the cases into piR-017724-high and piR-017724-low groups. We further analysed the correlations between piR-017724 expression and diferent clinical features (Table 2). The results showed that the expression level of piR-017724 was significantly correlated with the malignant progression of HCC. The piR-017724 expression in patients with advanced HCC (stage I-II) was signifcantly higher than that in patients with early HCC (stage III-IV).
Table 2
| Clinical characteristic | piR-017724 expression | P-value | |
|---|---|---|---|
| Low (n=22) | High (n=22) | ||
| Sex | 1.000 | ||
| Male | 17 (77.27%) | 18 (81.82%) | |
| Female | 5 (22.73%) | 4 (18.18%) | |
| Age | 0.069 | ||
| ≥60 | 7 (31.82%) | 13 (59.09%) | |
| <60 | 15 (68.18%) | 9 (40.91%) | |
| Tumor size, cm | 3.64 ± 2.02 | 4.92 ± 2.23 | 0.052 |
| Tumor stage | 0.042 | ||
| I-II | 3 (13.64%) | 9 (40.91%) | |
| III-IV | 19 (86.36%) | 13 (59.09%) | |
| Vascular invasion | 0.642 | ||
| Yes | 5 (22.73%) | 8 (36.36%) | |
| No | 4 (18.18%) | 3 (13.64%) | |
| Missing | 13 (59.09%) | 11 (50.00%) | |
| AFP, ng/mL | 147.40 [3.23, 1046.32] | 190.32 [3.94, 2234.50] | 0.778 |
| ALT, U/L | 33.00 [17.00, 52.50] | 27.00 [20.00, 46.50] | 0.900 |
| AST, U/L | 31.00 [26.00, 51.50] | 31.00 [26.50, 44.00] | 0.867 |
Correlation between piR-017724 and clinical characteristics.
P-value ≤ 0.05 indicate statistical significance.
The survival analysis showed that the average survival time of 22 patients with low piR-017724 expression was 59.98 ± 5.94 months and that of 22 patients with high piR-017724 expression was 87.33 ± 5.17 months. The piR-017724 expression was associated with the survival of patients with HCC. The prognosis of patients with HCC presenting low piR-017724 expression was signifcantly poor (Figure 1C).
The piR-017724 inhibits the proliferation of HCC cells
We perturbed the expression of piR-017724 in SMMC-7721 and PLC/PRF/5 cells with mimics or inhibitors to analyze its biological function (Figures 1D, E). As shown by the CCK-8 assay, inhibition of piR-017724 expression resulted in a significant increase in the viability of SMMC-7721 and PLC/PRF/5 cells, while increasing piR-017724 expression decreased the viability of both cell lines (Figures 2A, B). Similarly, colony formation assays confirmed that piR-017724 reduced the number of SMMC-7721 and PLC/PRF/5 colonies (Figures 2C, D). This indicated that piR-017724 can inhibit the proliferation of HCC cells.
Figure 2
The piR-017724 did not affect the apoptosis of HCC cells
The apoptosis of SMMC-7721 and PLC/PRF/5 cells was detected by flow cytometry. The above results indicated that piR-017724 did not affect the apoptosis of HCC cells (Figure 3).
Figure 3
The piR-017724 inhibits the migration/invasion ability of HCC cells
The ability to metastasize is assessed primarily through cell invasion and migration. The Transwell results showed that hsa_piR_017724 knockdown increased the migration ability of both cell lines compared with the in-NC group, while hsa_piR_017724 overexpression inhibited the migration ability of both cell lines compared with the mi-NC group (Figures 4A, B). We then tested the invasive ability of HCC cells by Matrigel transwell assay. Compared with the mi-NC group, hsa_piR_017724 overexpression inhibited the invasion of SMMC-7721 and PLC/PRF/5 cells, while cell invasion was enhanced in the hsa_piR_017724 inhibitor group compared with the in-NC group (Figures 4C, D). These results indicated that hsa_piR_017724 could inhibit the invasion and migration ability of hepatoma cells.
Figure 4
The piR-017724 inhibits HCC development by silencing PLIN3
Through high-throughput sequencing technology (Figure 5A) and bioinformatics analysis, the results suggest that the piR-017724 may potentially target GLRX3, HACD3, PLIN3, ZDHHC5, PRKAB2, GBF1 gene.
Figure 5
We then performed PCR verification: In SMMC-7721 and PLC/PRF/5 cells, compared with in-NC group, piR-017724 knockdown increased the expression of PLIN3, while compared with mi-NC group, piR-017724 overexpression decreased the expression of PLIN3 (Figures 5B, C). These results show that PLIN3 is a potential target of piR-017724 in HCC cells.
PLIN3 expression is significantly upregulated in HCC and is associated with poor prognosis
We analyzed in the TCGA database and found that PLIN3 was highly expressed in HCC compared with adjacent normal tissues (Figures 5D, E). The correlation between the expression of PLIN3 and the pathological stage of cancer was observed through the “pathological stage map” module of HEPIA2. It was found that the expression of PLIN3 was related to the pathological stage. Cancer cases were divided into high expression group and low expression group according to the expression level of PLIN3, and the correlation between the expression of PLIN3 and the prognosis of HCC patients was studied using TCGA data set. It was found that the prognosis of HCC patients with high expression of PLIN3 was poor (Figures 5F, G).
Therefore, we speculate that piR-017724 inhibits the development of HCC by silencing PLIN3.
Discussion
PIWI-interacting RNAs (piRNAs) are a new class of small ncRNAs (16, 17). To date, more than 20,000 piRNAs have been identified (18, 19). Some studies have shown that piRNAs are widely expressed in germ cells. Recently, high-throughput sequencing has shown that their signaling pathways are also active in somatic cells, particularly in human cancers (20–24), suggesting that they may play a role in carcinogenesis. piRNAs can affect multiple processes in cancer cells, including apoptosis, proliferation, migration, and invasion, by regulating gene expression at the transcriptional and posttranscriptional levels (21, 25). piRNAs have also been shown to exhibit pro-cancer or anticancer effects by directly binding to PIWI proteins (26). In recent years, by studying the roles of piRNAs and PIWI in cancer, scientists have found little evidence supporting a close link between piRNA/PIWI and various tumors. Aberrant expression of piRNAs is associated with various cancers and may play a pro-cancer or anticancer role in the occurrence, development and metastasis of cancer. The potential clinical implications of piRNA and PIWI as cancer diagnostic tools, therapeutic targets, and prognostic biomarkers are important. It has been reported that piRNAs are closely related to the malignancy of gastric cancer (27–29). The abnormal expression of piR-651 and piR-823 in normal and cancer tissues was closely related to the prognosis of gastric cancer and could be used as diagnostic tools or therapeutic targets for gastric cancer. Several studies have indicated that piRNAs play an important role in the pathogenesis of breast cancer and could be used as diagnostic markers (30–32). In renal cancer, studies have shown that piRNAs are closely related to the metastasis and prognosis of renal cancer (33–35). In colorectal cancer, piRNAs have important clinical significance as diagnostic tools and therapeutic targets (36–41). Compared with normal lung tissue, the expression of piR-55490 was decreased in lung cancer tissue, and inhibition of piR-55490 could promote the proliferation of lung cancer cells by inhibiting the activation of the mTOR pathway in lung cancer cells. This finding suggests that piR-55490 may have an anticancer effect in the development of lung cancer (24). piR-651 is involved in the occurrence, invasion and metastasis of non-small cell lung cancer and may be a potential cancer diagnostic tool (42–44).
Many studies have shown that Lipid droplets (LDs) are complex, dynamic and multifunctional organelles that play an important role in membrane transport, protein degradation, signal transduction and gene expression regulation (16). Members of the abdominal lipoprotein (PLIN) family are the most important LD-related proteins because they participate in the formation and degradation of LD. In addition, the PLIN family is composed of five member proteins, which have a conservative structure and the ability to bind intracellular LD (17, 18). Recent studies have shown that the abnormal expression of genes in the PLIN family may be a potential prognostic biomarker for various types of cancer, including sarcoma, hepatocellular carcinoma, renal carcinoma and breast cancer (19–22).
In our study, we first preliminarily confirmed the significant low expression of piR-017724 in HCC and its significant correlation with the malignant progression and poor prognosis of HCC patients, indicating that piR-017724 is a potential biomarker and therapeutic target for HCC; Subsequently, in vitro experiments confirmed that HCC cells can enhance their proliferation, invasion, and migration abilities by downregulating the expression of piR-017724. In addition, our study also found that piR-017724 may inhibit the development of HCC by targeting the silencing of PLIN3 expression. However, our current research can only determine the targeting effect of piR-017724 and PLIN3, so further research is needed in the future to explore the specific mechanism of piR-017724 involvement in the occurrence and development of HCC.
Conclusion
In summary, This study identified piR-017724 as a new HCC biomarker that participates in the occurrence and development of HCC by targeting PLIN3 as a new mechanism, which provides new insights into the clinical application of piR-017724 in the treatment of HCC.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.
Ethics statement
The studies involving human participants were reviewed and approved by the Ethics Committee of Affiliated Nantong Hospital 3 of Nantong University. The patients/participants provided their written informed consent to participate in this study.
Author contributions
Study concept and design: ML, YN, W-HC and LC. Experiment and data acquisition: JW, H-XW, Y-JW, L-LJ and L-XY. Analysis and interpretation of data: PZ and L-LJ. Statistical analysis: PZ and JW. Drafting of the manuscript: Y-JW and JW. Funding: Y-LC and ML. All authors contributed to the article and approved the submitted version.
Funding
This study was supported by the Nantong Science and Technology Plan Project (Grant/Award Numbers: JCZ2022036) and Nantong Social Development Plan Project (Grant/Award Numbers: MS12021045).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
SiegelRLMillerKDFuchsHEJemalA. Cancer statistics, 2021. CA Cancer J Clin (2021) 71:7–33. doi: 10.3322/caac.21654
2
LinJZhangHYuHBiXZhangWYinJet al. Epidemiological characteristics of primary liver cancer in mainland China from 2003 to 2020: a representative multicenter study. Front Oncol (2022) 12:906778. doi: 10.3389/fonc.2022.906778
3
RumgayHFerlayJde MartelCGeorgesDIbrahimASZhengRet al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer (2022) 161:108–18. doi: 10.1016/j.ejca.2021.11.023
4
ÁlvarezEGDemeulemeesterJOteroPJollyCGarcía-SoutoDPequeño-ValtierraAet al. Aberrant integration of hepatitis b virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture. Nat Commun (2021) 12:6910. doi: 10.1038/s41467-021-26805-8
5
LockartIYeoMGHHajarizadehBDoreGJDantaM. HCC incidence after hepatitis c cure among patients with advanced fibrosis or cirrhosis: a meta-analysis. Hepatology (2022) 76:139–54. doi: 10.1002/hep.32341
6
SeoWGaoYHeYSunJXuHFengDet al. ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles. J Hepatol (2019) 71:1000–11. doi: 10.1016/j.jhep.2019.06.018
7
European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 56(4):908–43. doi: 10.1016/j.jhep.2011.12.001
8
FornerAReigMBruixJ. Hepatocellular carcinoma. Lancet (2018) 391:1301–14. doi: 10.1016/s0140-6736
9
SimHWKnoxJ. Hepatocellular carcinoma in the era of immunotherapy. Curr Probl Cancer (2018) 42:40–8. doi: 10.1016/j.currproblcancer.2017.10.007
10
FerlayJShinHRBrayFFormanDMathersCParkinDM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 127:2893–917. doi: 10.1002/ijc.25516
11
XiaoYKeA. PIWI takes a giant step. Cell (2016) 167:310–12. doi: 10.1016/j.cell.2016.09.043
12
AssumpçãoCBCalcagnoDQAraújoTMSantosSESantos ÂKRigginsGJet al. The role of piRNA and its potential clinical implications in cancer. Epigenomics (2015) 7:975–84. doi: 10.2217/epi.15.37
13
MeiYWangYKumariPShettyACClarkDGableTet al. A piRNA-like small RNA interacts with and modulates p-ERM proteins in human somatic cells. Nat Commun (2015) 6:7316. doi: 10.1038/ncomms8316
14
NgKWAndersonCMarshallEAMinatelBCEnfieldKSSaprunoffHLet al. Piwi-interacting RNAs in cancer: emerging functions and clinical utility. Mol Cancer (2016) 15:5. doi: 10.1186/s12943-016-0491-9
15
ZhongFZhouNWuKGuoYTanWZhangHet al. A SnoRNA-derived piRNA interacts with human interleukin-4 pre-mRNA and induces its decay in nuclear exosomes. Nucleic Acids Res (2015) 43:10474–91. doi: 10.1093/nar/gkv954
16
GirardASachidanandamRHannonGJCarmellMA. A germline-specific class of small RNAs binds mammalian piwi proteins. Nature (2006) 442:199–202. doi: 10.1038/nature04917
17
GrivnaSTBeyretEWangZLinH. A novel class of small RNAs in mouse spermatogenic cells. Genes Dev (2006) 20:1709–14. doi: 10.1101/gad.1434406
18
Sai LakshmiSAgrawalS. piRNABank: a web resource on classified and clustered piwi-interacting RNAs. Nucleic Acids Res (2008) 36:D173–7. doi: 10.1093/nar/gkm696
19
ZhangPSiXSkogerbøGWangJCuiDLiYet al. piRBase: a web resource assisting piRNA functional study. Database (Oxford) (2014) 2014:bau110. doi: 10.1093/database/bau110
20
FathizadehHAsemiZ. Epigenetic roles of PIWI proteins and piRNAs in lung cancer. Cell Biosci (2019) 9:102. doi: 10.1186/s13578-019-0368-x
21
GuoBLiDDuLZhuX. piRNAs: biogenesis and their potential roles in cancer. Cancer Metastasis Rev (2020) 39:567–75. doi: 10.1007/s10555-020-09863-0
22
HyunS. Small RNA pathways that protect the somatic genome. Int J Mol Sci (2017) 18(5):912. doi: 10.3390/ijms18050912
23
RossRJWeinerMMLinH. PIWI proteins and PIWI-interacting RNAs in the soma. Nature (2014) 505:353–59. doi: 10.1038/nature12987
24
PengLSongLLiuCLvXLiXJieJet al. piR-55490 inhibits the growth of lung carcinoma by suppressing mTOR signaling. Tumour Biol (2016) 37:2749–56. doi: 10.1007/s13277-015-4056-0
25
LiuYDouMSongXDongYLiuSLiuHet al. The emerging role of the piRNA/piwi complex in cancer. Mol Cancer (2019) 18:123. doi: 10.1186/s12943-019-1052-9
26
ZengQWanHZhaoSXuHTangTOwareKAet al. Role of PIWI-interacting RNAs on cell survival: proliferation, apoptosis, and cycle. IUBMB Life (2020) 72:1870–78. doi: 10.1002/iub.2332
27
LinXXiaYHuDMaoQYuZZhangHet al. Transcriptome−wide piRNA profiling in human gastric cancer. Oncol Rep (2019) 41:3089–99. doi: 10.3892/or.2019.7073
28
MartinezVDEnfieldKSSRowbothamDALamWL. An atlas of gastric PIWI-interacting RNA transcriptomes and their utility for identifying signatures of gastric cancer recurrence. Gastric Cancer (2016) 19:660–65. doi: 10.1007/s10120-015-0487-y
29
ChengJDengHXiaoBZhouHZhouFShenZet al. piR-823, a novel non-coding small RNA, demonstrates in vitro and in vivo tumor suppressive activity in human gastric cancer cells. Cancer Lett (2012) 315:12–7. doi: 10.1016/j.canlet.2011.10.004
30
HashimARizzoFMarcheseGRavoMTaralloRNassaGet al. RNA Sequencing identifies specific PIWI-interacting small non-coding RNA expression patterns in breast cancer. Oncotarget (2014) 5:9901–10. doi: 10.18632/oncotarget.2476
31
KrishnanPGhoshSGrahamKMackeyJRKovalchukODamarajuS. Piwi-interacting RNAs and PIWI genes as novel prognostic markers for breast cancer. Oncotarget (2016) 7:37944–56. doi: 10.18632/oncotarget.9272
32
HuangGHuHXueXShenSGaoEGuoGet al. Altered expression of piRNAs and their relation with clinicopathologic features of breast cancer. Clin Transl Oncol (2013) 15:563–8. doi: 10.1007/s12094-012-0966-0
33
LiYWuXGaoHJinJMLiAXKimYSet al. (piRNAs) are dysregulated in renal cell carcinoma and associated with tumor metastasis and cancer-specific survival. Mol Med (2015) 21:381–8. doi: 10.2119/molmed.2014.00203
34
BuschJRallaBJungMWotschofskyZTrujillo-ArribasESchwabePet al. Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas. J Exp Clin Cancer Res (2015) 34:61. doi: 10.1186/s13046-015-0180-3
35
ZhaoCTolkachYSchmidtDTomaMMudersMHKristiansenGet al. Mitochondrial PIWI-interacting RNAs are novel biomarkers for clear cell renal cell carcinoma. World J Urol (2019) 37:1639–47. doi: 10.1007/s00345-018-2575-1
36
MaiDDingPTanLZhangJPanZBaiRet al. PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. Theranostics (2018) 8:5213–30. doi: 10.7150/thno.28001
37
YinJJiangXYQiWJiCGXieXLZhangDXet al. piR-823 contributes to colorectal tumorigenesis by enhancing the transcriptional activity of HSF1. Cancer Sci (2017) 108:1746–56. doi: 10.1111/cas.13300
38
YinJQiWJiCGZhangDXXieXLDingQet al. Small RNA sequencing revealed aberrant piRNA expression profiles in colorectal cancer. Oncol Rep (2019) 42:263–72. doi: 10.3892/or.2019.7158
39
WengWLiuNToiyamaYKusunokiMNagasakaTFujiwaraTet al. Novel evidence for a PIWI-interacting RNA . (piRNA) as an oncogenic mediator of disease progression, and a potential prognostic biomarker in colorectal cancer. Mol Cancer (2018) 17:16. doi: 10.1186/s12943-018-0767-3
40
SunRGaoCLLiDHLiBJDingYH. Expression status of PIWIL1 as a prognostic marker of colorectal cancer. Dis Markers (2017) 2017:1204937. doi: 10.1155/2017/1204937
41
Vychytilova-FaltejskovaPStitkovcovaKRadovaLSachlovaMKosarovaZSlabaKet al. Circulating PIWI-interacting RNAs piR-5937 and piR-28876 are promising diagnostic biomarkers of colon cancer. Cancer Epidemiol Biomarkers Prev (2018) 27:1019–28. doi: 10.1158/1055-9965.Epi-18-0318
42
YaoJWangYWFangBBZhangSJChengBL. piR-651 and its function in 95-d lung cancer cells. BioMed Rep (2016) 4:546–50. doi: 10.3892/br.2016.628
43
ZhangSJYaoJShenBZLiGBKongSSBiDDet al. Role of piwi-interacting RNA-651 in the carcinogenesis of non-small cell lung cancer. Oncol Lett (2018) 15:940–46. doi: 10.3892/ol.2017.7406
44
LiDLuoYGaoYYangYWangYXuYet al. piR-651 promotes tumor formation in non-small cell lung carcinoma through the upregulation of cyclin D1 and CDK4. Int J Mol Med (2016) 38:927–36. doi: 10.3892/ijmm.2016.2671
Summary
Keywords
hepatocellular carcinoma, piR-017724, proliferation, migration, invasion, PLIN3
Citation
Wu Y-J, Wang J, Zhang P, Yuan L-X, Ju L-L, Wang H-X, Chen L, Cao Y-L, Cai W-H, Ni Y and Li M (2023) PIWIL1 interacting RNA piR-017724 inhibits proliferation, invasion, and migration, and inhibits the development of HCC by silencing PLIN3. Front. Oncol. 13:1203821. doi: 10.3389/fonc.2023.1203821
Received
11 April 2023
Accepted
26 June 2023
Published
11 July 2023
Volume
13 - 2023
Edited by
Xu Zhang, Jiangsu University, China
Reviewed by
Runbi Ji, Jiangsu University Affiliated People’s Hospital, China; Xu Wang, Affiliated Hospital of Jiangsu University, China
Updates
Copyright
© 2023 Wu, Wang, Zhang, Yuan, Ju, Wang, Chen, Cao, Cai, Ni and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Min Li, lmntsy@163.com; Yi Ni, 15996671038@163.com; Wei-Hua Cai, cwhntsy@163.com
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.